Forte Biosciences Stock Jumps as argenx Agrees to $2.2 Billion Cash Deal
Forte Biosciences shares climbed sharply in pre-market trading after argenx announced a definitive agreement to buy the clinical-stage company for $77 per share in cash, valuing Forte at about $2.2 billion. The offer represents large premiums to recent prices and follows positive Phase 1b data for Forte's lead program, FB102, in two autoimmune indi…